KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $915.7 million.

  • Alnylam Pharmaceuticals' Non-Current Assets fell 307.28% to $915.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year increase of 621.66%. This contributed to the annual value of $915.7 million for FY2025, which is 307.28% down from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Non-Current Assets is $915.7 million, which was down 307.28% from $898.9 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Non-Current Assets registered a high of $945.6 million during Q1 2025, and its lowest value of $784.3 million during Q2 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Non-Current Assets averaged around $859.1 million, with its median value being $850.3 million (2023).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Non-Current Assets tumbled by 3539.4% in 2021 and then surged by 1313.43% in 2025.
  • Alnylam Pharmaceuticals' Non-Current Assets (Quarter) stood at $834.7 million in 2021, then rose by 2.32% to $854.1 million in 2022, then decreased by 0.81% to $847.2 million in 2023, then increased by 11.51% to $944.7 million in 2024, then decreased by 3.07% to $915.7 million in 2025.
  • Its last three reported values are $915.7 million in Q4 2025, $898.9 million for Q3 2025, and $922.3 million during Q2 2025.